Discover more about our CEO, Benjamin Fryer, his inspiration behind founding Pluristyx, and our exciting plans for 2025 in a recent interview conducted by Bullpen at JPM2025.
Our commitment to revolutionizing regenerative medicine aligns perfectly with the spirit of this event. We're proud to support the development of groundbreaking cellular therapies that have the potential to transform patient care.
Dr. Ben Fryer, Co-Founder and CEO of Pluristyx, presented to webinar participants the “how and why” of integrating high quality ancillary raw materials into cell therapy product development and the manufacturing workflow, beginning with the starting cell source and MCB
Professor Clare Parish BBiomedSci, PhD; NHMRC Senior Research Fellow; Stem Cells and Neural Development laboratory; Florey Institute of Neuroscience & Mental Health; The University of
MAKING CELL THERAPY SAFE: Cell therapies are largely derived from induced pluripotent cells or embryonic cells and have the potential of reverting back to the
